Sunil Nagpal is an Oncology physician affiliated with West Michigan Cancer Center. OpenAlex indexes 13 publications with 298 citations (h-index 4); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
805 John Street
Kalamazoo, MI 49007
Telephone
269-286-7170Provider last certified this registry record 15 Jan 2021.
Clinical trials
- The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients
Sponsor: McLaren Regional Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202513 payments
- Tempus AI, IncProgram year20253 payments
- Astellas Pharma US IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65%Aromatase Inhibitor45.7%Anastrozole66%Letrozole24%Exemestane10%Part D≥214 patientsKinase inhibitor7.2%Ibrance57%Jakafi14%Verzenio12%Imbruvica11%Brukinsa7%Part D<11 patients+ 5 more classes in this area
Nervous system
12.6%Gabapentinoids3.5%Gabapentin100%Part D≥18 patientsOpioid Agonist3.1%Oxycodone-Acetaminophen49%Oxycodone Hcl34%Morphine Sulfate Er18%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
9.9%Corticosteroid3.1%Prednisone100%Part D≥17 patientsSerotonin-3 Receptor Antagonist2.4%Ondansetron Hcl79%Ondansetron Odt21%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- EP.04E.02 Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis
Journal of Thoracic Oncology
2024 - P62.02 A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes
Journal of Thoracic Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”